X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TORRENT PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TORRENT PHARMA GLENMARK PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 13.5 25.5 53.0% View Chart
P/BV x 3.6 6.2 57.4% View Chart
Dividend Yield % 0.3 3.2 10.5%  

Financials

 GLENMARK PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
TORRENT PHARMA
Mar-16
GLENMARK PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs9931,720 57.7%   
Low Rs7291,134 64.3%   
Sales per share (Unadj.) Rs325.5394.5 82.5%  
Earnings per share (Unadj.) Rs39.3101.8 38.6%  
Cash flow per share (Unadj.) Rs48.7116.3 41.8%  
Dividends per share (Unadj.) Rs2.0040.00 5.0%  
Dividend yield (eoy) %0.22.8 8.3%  
Book value per share (Unadj.) Rs159.2200.3 79.5%  
Shares outstanding (eoy) m282.17169.22 166.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.6 73.2%   
Avg P/E ratio x21.914.0 156.3%  
P/CF ratio (eoy) x17.712.3 144.3%  
Price / Book Value ratio x5.47.1 75.9%  
Dividend payout %5.139.3 13.0%   
Avg Mkt Cap Rs m242,991241,435 100.6%   
No. of employees `00013.010.9 119.1%   
Total wages/salary Rs m16,4088,559 191.7%   
Avg. sales/employee Rs Th7,083.96,129.6 115.6%   
Avg. wages/employee Rs Th1,265.4785.8 161.0%   
Avg. net profit/employee Rs Th855.11,581.3 54.1%   
INCOME DATA
Net Sales Rs m91,85766,764 137.6%  
Other income Rs m3742,156 17.3%   
Total revenues Rs m92,23068,920 133.8%   
Gross profit Rs m20,36727,204 74.9%  
Depreciation Rs m2,6442,461 107.4%   
Interest Rs m2,3731,859 127.7%   
Profit before tax Rs m15,72425,041 62.8%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-1,403 57.7%   
Tax Rs m3,8276,414 59.7%   
Profit after tax Rs m11,08817,224 64.4%  
Gross profit margin %22.240.7 54.4%  
Effective tax rate %24.325.6 95.0%   
Net profit margin %12.125.8 46.8%  
BALANCE SHEET DATA
Current assets Rs m68,74646,622 147.5%   
Current liabilities Rs m27,02732,843 82.3%   
Net working cap to sales %45.420.6 220.1%  
Current ratio x2.51.4 179.2%  
Inventory Days Days8574 114.5%  
Debtors Days Days9679 120.9%  
Net fixed assets Rs m24,13239,029 61.8%   
Share capital Rs m282846 33.3%   
"Free" reserves Rs m44,64331,400 142.2%   
Net worth Rs m44,92533,890 132.6%   
Long term debt Rs m45,36318,637 243.4%   
Total assets Rs m117,63990,136 130.5%  
Interest coverage x7.614.5 52.7%   
Debt to equity ratio x1.00.5 183.6%  
Sales to assets ratio x0.80.7 105.4%   
Return on assets %11.421.2 54.0%  
Return on equity %24.750.8 48.6%  
Return on capital %19.148.5 39.4%  
Exports to sales %043.3 0.0%   
Imports to sales %06.9 0.0%   
Exports (fob) Rs mNA28,934 0.0%   
Imports (cif) Rs mNA4,584 0.0%   
Fx inflow Rs m56,15229,185 192.4%   
Fx outflow Rs m8,0846,021 134.3%   
Net fx Rs m48,06823,165 207.5%   
CASH FLOW
From Operations Rs m6,57427,132 24.2%  
From Investments Rs m-7,124-7,014 101.6%  
From Financial Activity Rs m5,432-14,352 -37.8%  
Net Cashflow Rs m1,9925,767 34.6%  

Share Holding

Indian Promoters % 48.3 71.5 67.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.0 98.3%  
FIIs % 34.4 12.6 273.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   56,727 26,511 214.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   CADILA HEALTHCARE  J.B.CHEMICALS  ORCHID PHARMA LTD  DISHMAN PHARMA  FULFORD INDIA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 20, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - DR. DATSONS LABS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS